3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Observational
2
Interventional
1
Sponsor
Conditions
Multiple Myeloma
7
Prostatic Neoplasms
3
Lymphoma
3
Plasmacytoma
2
Paraproteinemias
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Leukemia, Plasma Cell
2
Breast Neoplasms
2
Anatomic Stage IV Breast Cancer AJCC v8
2
Spinal Cord Compression
1
Recurrence
1
Radiation Injuries
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
Myasthenia Gravis
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hepatitis
1
Hemangioma
1
Head and Neck Neoplasms
1
Glioma
1
Gallstones
1
Esophageal Stenosis
1
Interventions
rozanolixizumab
10
zilucoplan
8
efgartigimod alfa
8
Rituximab
7
Cyclophosphamide
7
telitacicept
6
fludarabine
6
eculizumab
5
Prednisone
5
ravulizumab
4
Pyridostigmine Bromide
4
Immunoglobulins, Intravenous
4
Hizentra
4
Tacrolimus
3
Mycophenolic Acid
3
HBM9161
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Prednisolone
2
Exercise
2
tofacitinib
1
tocilizumab
1
talquetamab
1
satralizumab
1
sargramostim
1
rhoA GTP-Binding Protein
1
remibrutinib
1
prednylidene
1
iscalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Myasthenia Gravis
×
Steroids
×
Clear all
NCT00995722
2017-06-02
EPITOME'
University of Miami
Phase 3
Terminated
11 enrolled
14 charts